Late incidence and determinants of reoperation in patients with prosthetic heart valves q
|
|
- Myron Leonard
- 5 years ago
- Views:
Transcription
1 European Journal of Cardio-thoracic Surgery 25 (2004) Abstract Late incidence and determinants of reoperation in patients with prosthetic heart valves q Marc Ruel a,b, *, Alexander Kulik a, Fraser D. Rubens a, Pierre Bédard a, Roy G. Masters a, Andrew L. Pipe a, Thierry G. Mesana a a Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Suite 3403, Ottawa, Ont., Canada K1Y 4W7 b Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada K1H 8M5 Received 19 October 2003; received in revised form 7 December 2003; accepted 15 December 2003 Objectives: Reoperation is a relatively common event in patients with prosthetic heart valves, but its actual occurrence can vary widely from one patient to another. With a focus on bioprosthetic valves, this study examines risk factors for reoperation in a large patient cohort. Methods: Patients ðn ¼ 3233Þ who underwent a total of 3633 operations for aortic (AVR) or mitral valve replacement (MVR) between 1970 and 2002 were prospectively followed (total patient-years; mean 6.6 ^ 5.0 years; maximum 32.4 years). The incidence of prosthetic valve reoperation and the impact of patient- and valve-related variables were determined with actual and actuarial methods. Results: Fifteenyear actual freedom from all-cause reoperation was 94.1% for aortic mechanical valves, 61.4% for aortic bioprosthetic valves, 94.8% for mitral mechanical valves, and 63.3% for mitral bioprosthetic valves. In both aortic and mitral positions, current bioprosthesis models had significantly better durability than discontinued bioprostheses (15-year reoperation odds-ratio 0.11 ^ 0.04; P, 0:001 for aortic, and 0.42 ^ 0.14; P ¼ 0:009 for mitral). Current bioprostheses were significantly more durable in the aortic position than in the mitral position (14.3 ^ 6.8% more freedom from 15-year reoperation; P ¼ 0:018). Older age was protective, but smoking was an independent risk factor for reoperation after bioprosthetic AVR and MVR (hazard ratio for smoking 2.58 and 1.78, respectively). In patients with aortic bioprostheses, persistent left ventricular hypertrophy at follow-up and smaller prosthesis size predicted an increased incidence of reoperation, while this was not observed in patients with mitral bioprostheses. Conclusions: These analyses indicate that current bioprostheses have significantly better durability than discontinued bioprostheses, reveal a detrimental impact for smoking after AVR and MVR, and indicate an increased reoperation risk in patients with a small aortic bioprosthesis or with persistent left ventricular hypertrophy after AVR. q 2003 Elsevier B.V. All rights reserved. Keywords: Valves; Follow-up studies; Prosthesis; Surgery; Complications 1. Introduction Reoperation following valve replacement surgery is a relatively common event, particularly in patients with bioprosthetic valves. Freedom from reoperation for currently available mechanical valves is greater than 95% at 10 years and greater than 90% at 15 years. Bioprostheses, q Presented at the Joint 17th Annual Meeting of the European Association for Cardio-thoracic Surgery and the 11th Annual Meeting of the European Society of Thoracic Surgeons, Vienna, Austria, October 12 15, 2003 * Corresponding author. Address: Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Suite 3403, Ottawa, Ontario, Canada K1Y 4W7. Tel.: þ ; fax: þ address: mruel@ottawaheart.ca (M. Ruel). however, have a significantly higher rate of reoperation secondary to structural valve deterioration (SVD). In large series, freedom from reoperation has been greater than 95% at 5 years, greater than 90% at 10 years, but less than 70% at 15 years [1]. Although long-term anticoagulation is avoided with tissue valves, the risk of SVD, reoperation, and subsequent morbidity and mortality remain their major disadvantages [2]. Although some risk factors for earlier reoperation in patients with bioprosthetic valves are known, such as younger age [3] and mitral valve position [4], potential others such as poor ventricular function, valve model, and prosthesis size have been controversial [3,5 8]. This study aims at better defining the determinants of reoperation from a large cohort of patients with prosthetic heart valves followed longitudinally after aortic (AVR) or /$ - see front matter q 2003 Elsevier B.V. All rights reserved. doi: /j.ejcts
2 M. Ruel et al. / European Journal of Cardio-thoracic Surgery 25 (2004) mitral valve replacement (MVR), with an emphasis on reoperation for SVD of bioprostheses. 2. Methods 2.1. Patients, prostheses and follow-up Adult patients ($18 years of age) who underwent AVR or MVR between 1970 and 2002 at our institution were followed annually in a dedicated valve clinic. Patients had a history focused on the determination of functional status and the occurrence of valve-related complications, physical examination, ECG and chest radiograph, complete blood count, serum chemistries, and international normalized ratio determinations when applicable. The study cohort included 3233 consecutive adult patients who underwent a total of 3633 operations for replacement of the aortic, mitral, or both valves. Of these 3233 patients, no information is available on 291 (9.0%) who did not attend the follow-up valve clinic at any point in time, and only partial information could be obtained on an additional 350 patients (10.8%) who were later lost to follow-up at a mean of 4.7 ^ 4.3 years after valve replacement. Total follow-up was patient-years (mean 6.6 ^ 5.0 years; maximum 32.4 years). The preoperative characteristics of the cohort by site of implant are presented in Table 1. Two thousand three hundred forty-eight operations consisted of AVR, 1062 of MVR, and 223 of concomitant AVR and MVR. Table 2 shows the types of prostheses implanted in the study population All-cause reoperation and reoperation for structural valve degeneration In accordance with the Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular Operations [9], reoperation was defined as any operation that repaired, altered, or replaced a previously operated valve. Since this series excluded primary valve repair procedures, reoperation was performed for a previously implanted prosthesis in Table 1 Prevalence and mean values of preoperative variables, by implant site Aortic ðn ¼ 2348Þ Mitral ðn ¼ 1062Þ Double valve ðn ¼ 223Þ Gender Female (%) 31.8* Age (years) 61.9 ^ 13.6* 59.2 ^ ^ 12.4 Body surface area (m 2 ) 1.87 ^ 0.24* 1.76 ^ ^ 0.25 Coronary artery disease (%) 36.2* * Chronic atrial fibrillation (%) 5.3* Values reported as percentages or mean ^ SD. *P, 0:05 versus other subgroups. Table 2 Number and current commercial availability of implanted valve prostheses, by site all cases. The indication for reoperation was available for all patients. Reoperation for SVD was defined as a reoperation performed primarily because of an intrinsic abnormality of the valve that caused stenosis or regurgitation, exclusive of infection or thrombosis. Other prosthesis-related complications were recorded according to the guidelines [9] Statistical analyses Aortic* ðn ¼ 2571; %Þ Mitral* ðn ¼ 1285; %Þ Mechanical valves (%) St Jude Medical 413 (16.1) 253 (19.7) Y a Medtronic Hall 338 (13.2) 286 (22.3) Y Carbomedics 276 (10.7) 124 (9.7) Y Harken 83 (3.2) 58 (4.5) N Lillehei Kaster 69 (2.7) 20 (1.6) N Bjork Shiley 18 (0.7) 8 (0.6) N MCRI On-X 16 (0.6) 13 (1.0) Y Bioprosthetic valves (%) Medtronic Hancock II 441 (17.2) 140 (10.9) Y Ionescu Shiley 254 (9.9) 130 (10.1) N Ionescu Shiley low profile 205 (8.0) 102 (7.9) N Medtronic Hancock I 138 (5.4) 86 (6.7) Y Homograft 98 (3.8) Y Medtronic Intact 96 (3.7) 33 (2.6) N Edwards Perimount 79 (3.1) 30 (2.3) Y St Jude X-Cell 23 (0.9) 1 (0.1) N Stentless Porcine b 17 (0.7) Y Carpentier Edwards Standard 7 (0.3) 1 (0.1) Y Current availability *Prostheses implanted during double valve replacement were redistributed according to their individual implant site. N, no; Y, yes. a Includes 57 Silzone TM -coated aortic prostheses, which are now discontinued. b Denotes either a St Jude Toronto stentless or a Medtronic Freestyle prosthesis. Data were imported and analyzed in Intercooled Stata 8.0 (Stata, College Station, TX). For actuarial analyses, patients were censored at the time of their last follow-up visit or death if they had not yet been reoperated. Censoring was assumed to be independent of predictors and outcomes. Actual freedom from all-cause reoperation or reoperation for SVD was determined for each site of implantation and each class (i.e. mechanical versus bioprosthetic) of valve prostheses [6,10]. Crude actuarial reoperation rates are not reported. To increase the study s generalizability with respect to current cardiac surgical practice, separate analyses were also performed that only included patients who were implanted with currently available prostheses. Potential univariate predictors were individually tested for equality of actuarial freedom from reoperation with a Log-Rank test. These predictors were also tested for 15-year
3 366 M. Ruel et al. / European Journal of Cardio-thoracic Surgery 25 (2004) actual freedom from reoperation with logistic regression. Univariate effect estimates and P-values were used to guide multivariate model selection and are not reported Reoperation due to structural valve deterioration hazard (actuarial) No a priori distributional assumption was made with respect to the freedom from reoperation over time, and the proportional hazard assumption was tested for each covariate with generalized Cox Snell residuals and 2 ln[2ln(survival)] probabilities. Cox proportional hazards models were developed by incorporating variables that had a P-value of 0.10 or less on univariate analysis; in order to account for positive or negative confounding, no automated model selection procedure was used and all reported variables, unless collinear with a Spearman s rank correlation coefficient $ 0.30 and a P-value, 0.005, were used simultaneously. When collinear covariates were identified, the one most readily interpretable was selected for entry in the final models. Non-significant variables used in the models are presented in the footnotes of Tables 3 and 4. Each model was evaluated with a score test and rejected if P $ 0:05: Reoperation due to SVD at 15 Years (actual) The impact on the 15-year reoperation incidence of variables that had a P-value of 0.10 or less on univariate analysis or that were significant on multivariate actuarial analysis was validated with logistic regression. Only variables that predicted reoperation for SVD by using both actuarial and actual methods are reported in Tables 3 and 4. Table 3 Actuarial predictors of reoperation for structural valve deterioration aortic bioprostheses Adjusted hazard ratio 95% CI P Significant predictors a Female gender , Age (per year) , 0.98,0.001 Body surface area (per m 2 ) , Smoking , 3.60,0.001 Persistent LVH at follow-up , 3.51,0.001 Current bioprosthesis , (versus discont.) Prosthesis size , (per manufacturer size unit) Prosthesis size/bsa #10th percentile b , BSA, body surface area; Discont., discontinued bioprosthesis model; LVH, left ventricular hypertrophy. a Non-significant variables included in the model were atrial fibrillation, coronary disease, diabetes mellitus, preoperative New York Heart Association class, redo aortic valve replacement, and aspirin use. b Separate model. Table 4 Actuarial predictors of reoperation for structural valve deterioration mitral bioprostheses No automated selection procedure was used, and collinearity was handled as previously described. 3. Results Adjusted hazard ratio 95% CI P Significant predictors a Age (per year) , Coronary artery disease , Smoking , a Non-significant variables included in the model were female gender, atrial fibrillation, diabetes mellitus, body surface area, preoperative New York Heart Association class, redo mitral valve replacement, current mitral bioprosthesis (versus discontinued), mitral prosthesis size, persistent left ventricular hypertrophy at follow-up, and aspirin use Cumulative incidence of reoperation after valve replacement All-cause reoperation Actual freedom from all-cause reoperation at 10, 15 and 20 years was 96.2, 94.1, and 93.8% for aortic mechanical valves, 76.1, 61.4, and 59.6% for aortic bioprosthetic valves (P, 0:001; versus aortic mechanical), 96.4, 94.8, and 94.2% for mitral mechanical valves, and 79.8, 63.3, and 57.6% for mitral bioprosthetic valves (P, 0:001; versus mitral mechanical), respectively Reoperation for structural valve deterioration Fig. 1 displays the actual freedom from reoperation for SVD in patients with aortic (A) and mitral (B) bioprostheses, and separately depicts discontinued and current bioprosthesis models. In both aortic and mitral positions, current bioprostheses had significantly better durability than discontinued bioprostheses (odds-ratio of 15-year reoperation for SVD 0.11 ^ 0.04; 95% CI 0.06, 0.23; P, 0:001 for current versus discontinued aortic bioprostheses, and 0.42 ^ 0.14; 95% CI 0.22, 0.80; P ¼ 0:009 for current versus discontinued mitral bioprostheses, respectively). Current bioprostheses were significantly more durable in the aortic position than in the mitral position (14.3 ^ 6.8% more freedom from 15-year reoperation for SVD; 95% CI 1.1, 27.7%; P ¼ 0:018; current aortic versus mitral bioprostheses). For example, in 91 patients at risk 10 years after AVR with the Medtronic Hancock II aortic prosthesis, 95.8% were free (94.8 ^ 3.2% by actuarial methods) from reoperation due to SVD. There was no significant difference in the durability of discontinued bioprosthesis between aortic and mitral implant positions.
4 M. Ruel et al. / European Journal of Cardio-thoracic Surgery 25 (2004) Fig. 1. Actual freedom from reoperation due to structural valve deterioration in patients with discontinued versus current aortic (A) and mitral (B) bioprostheses Risk factors for reoperation due to structural valve deterioration (Tables 3 and 4) Gender Women had a lower incidence of reoperation for SVD after AVR (hazard ratio 0.67). This, however, was not the case after MVR, where a non-significant reverse trend was observed (hazard ratio, female versus male gender 1.50; 95% CI 0.88, 2.55; P ¼ 0:14) Coronary artery disease Concomitant coronary artery disease was protective against reoperation in patients undergoing bioprosthetic MVR. The hazard ratio was Smoking Smoking was an independent risk factor for reoperation due to SVD after AVR as well as after MVR. The hazard ratios were 2.58 and 1.78, respectively Age Older age was protective against reoperation for SVD after bioprosthetic AVR and MVR, with a hazard ratio of 0.97 and 0.98 per year increase in age, respectively Body surface area A larger body surface area (BSA) was associated with a lower freedom from reoperation for SVD after AVR (hazard ratio 1.84 per m 2 increase), but not after MVR Left ventricular hypertrophy Persistent left ventricular hypertrophy at follow-up was associated with a significantly higher incidence of subsequent reoperation for SVD in patients with aortic bioprostheses (hazard ratio 2.38) Prosthesis size In patients with aortic bioprostheses, larger prosthesis size significantly predicted an increased freedom from
5 368 M. Ruel et al. / European Journal of Cardio-thoracic Surgery 25 (2004) reoperation due to SVD. Both a linear effect with respect to manufacturer prosthesis size (hazard ratio 0.82 per increase of one valve size, independent of BSA), and a dichotomous effect of the ratio of prosthesis size over BSA at or below the 10th percentile value of the cohort were observed (hazard ratio 1.79 for patients with prosthesis size/bsa ratio smaller or equal to the 10th percentile value of the cohort). These relationships were not observed in patients with mitral bioprostheses. 4. Discussion This study identified three main new findings with respect to the late incidence of reoperation for SVD in patients with bioprosthetic heart valves. First, it formally demonstrated that current models of bioprostheses have markedly better durability than older models that are discontinued. This is an encouraging finding for clinicians and patients, and provides basis for the initiation of a reconsideration process on the existing guidelines regarding the generally recommended minimum age for the implantation of biological versus mechanical prostheses. Secondly, the study indicated that smoking has a detrimental effect on bioprosthetic valve durability, regardless of implant site. A related finding had previously been reported in patients with native aortic valve stenosis [11], but so far not in patients with bioprosthetic valves, and this provides another mandate for the cessation of smoking in all valve patients, notwithstanding the other effects of smoking on cancer and coronary disease risk. In this regard, one can speculate that smoking might play a role on calcium metabolism or accelerate SVD by a mechanism not unrelated to atherosclerosis. Finally, the study also showed that larger aortic bioprostheses have a lower incidence of reoperation. This may be due to patients with larger prostheses tolerating stenosis or regurgitation secondary to SVD better, or relate to a true beneficial impact of larger prosthesis size on SVD because of lower flow velocities and lower transprosthesis gradients. The study also identified a relationship between persistent left ventricular hypertrophy determined by objective ECG criteria at follow-up after AVR, and a higher incidence of reoperation for aortic SVD. Although the mechanistic basis of this relationship is unclear, it could relate to the coprevalence of left ventricular hypertrophy in patients with smaller aortic prostheses, in itself a risk factor for reoperation, or to the coprevalence of left ventricular hypertrophy with hypertension, which may cause chronically increased diastolic closure stress on the bioprosthesis. BSA also correlated with the risk of reoperation for aortic SVD. This is in contrast with a previous study that showed an inverse relationship between body mass index and native aortic valve stenosis (although valve disease-related weight loss could have confounded this relationship) [12], and could potentially be explained by higher hemodynamic stresses on the prosthesis in patients with an elevated BSA or by their lower tolerance to the effects of stenosis or regurgitation as the bioprosthesis progressively fails. Coexistent coronary artery disease at the time of bioprosthetic MVR resulted in a significantly increased freedom from reoperation in this study. This has been identified by other authors previously [10], and likely relates to competing risks of death in patients with concomitant mitral and coronary disease rather than to a true protective biological effect of coronary disease on the development of SVD Previous related work Structural deterioration of a bioprosthesis is the leading cause and most frequent indication for reoperation in patients with tissue valves [13 16]. Bioprosthetic valves are known to undergo a time-dependent process of structural deterioration secondary to stress-related tears, perforations or dystrophic calcifications [17]. Independent risk factors previously found to be associated with bioprosthetic SVD include younger age, mitral valve position [18 23], renal insufficiency [21], and poor ventricular function [3], although no relationship between left ventricular function and freedom from reoperation was demonstrated in the present study. Larger valve size had previously been suspected to be a possible predictor of SVD [6,24], but other studies have found the opposite to be true, with small valve size being associated with increased calcification [7] and stenotic failure [8] Limitations The findings of this cohort study may not necessarily be generalizable to all patients with bioprosthetic valves, because the study represents a single institution s experience and may have been affected by regional referral and patient management patterns. In addition, unsuspected demographic and selection factors unique to the cohort may have resulted in overfitted statistical associations. Finally, generalizability to current bioprostheses may be in part limited by the fact that most reoperations for SVD occurred in older generation bioprostheses, despite this factor having been accounted for in the analyses. No prospective data was available from the present cohort on serum cholesterol level and statin treatment status. Evidence suggests that hypercholesterolemia plays a role in the progression of native aortic stenosis [11,25], and recent findings unpublished as of this writing have identified a potential benefit for statins in preventing reoperation in patients with bioprosthetic valves. The impact of serum creatinine and renal failure could also not be evaluated, as too few dialysis-dependent patients had, until recently, been implanted with bioprosthetic valves at our institution. Because this study was observational it is possible, despite the use of a hard end-point like reoperation, that
6 M. Ruel et al. / European Journal of Cardio-thoracic Surgery 25 (2004) clinical factors or selection bias may have influenced results, such as in those patients for whom reoperation might have been delayed because of patient preferences or perceived surgical risk. In addition, although the effect of multiple potential confounders was forced into the statistical models, it remains possible that unknown confounders may ultimately have impacted on some findings Conclusions Despite the aforementioned limitations, this study identified several risk factors for reoperation due to structural valve dysfunction in patients with aortic and mitral bioprostheses. A major, potentially modifiable factor shown to be of detrimental impact in both aortic and mitral implant positions was smoking. In addition, the study revealed that larger aortic bioprosthesis size was associated with an increased freedom from late reoperation for SVD, therefore constituting an additional impetus to implant as large a valve as possible in all patients undergoing bioprosthetic AVR. Other risk factors for reoperation due to SVD included younger age, male gender, BSA, and persistent left ventricular hypertrophy for patients with aortic bioprostheses, and younger age and coronary artery disease for patients with mitral bioprostheses. The study also formally determined that current models of bioprostheses have markedly better durability than older models that are now discontinued, suggesting that a revision process on the recommended minimum age guidelines for the implantation of tissue versus mechanical prostheses may be indicated. Overall, the results of this study may provide useful information for clinicians and patients in determining what prosthesis class may be best suited for a given patient, how the prosthesis may fare with respect to reoperation for SVD, and how some risk factors for reoperation due to SVD may potentially be avoided. Acknowledgements The authors wish to extent their gratitude to Mary Thomson for her assistance with the organization of the valve clinic and management of the database. References [1] Poirer NC, Pelletier LC, Pellerin M, Carrier M. 15-year experience with the Carpentier Edwards pericardial bioprosthesis. Ann Thorac Surg 1998;66(Suppl 6):S57 S61. [2] Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003;41(6): [3] David TE, Ivanov J, Armstrong S, Feindel CM, Cohen G. Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg 2001;121(2): [4] Jones EL, Weintraub WS, Craver JM, Guyton RA, Cohen CL, Corrigan VE, Hatcher Jr CR. Ten-year experience with the porcine bioprosthetic valve: interrelationship of valve survival and patient survival in 1,050 valve replacements. Ann Thorac Surg 1990;49(3): discussion [5] Glower DD, Landolfo KP, Cheruvu S, Cen YY, Harrison JK, Bashore TM, Smith PK, Jones RH, Wolfe WG, Lowe JE. Determinants of 15- year outcome with 1,119 standard Carpentier-Edwards porcine valves. Ann Thorac Surg 1998;66(Suppl 6):S44 8. [6] Grunkemeier GL, Jamieson WR, Miller DC, Starr A. Actuarial versus actual risk of porcine structural valve deterioration. J Thorac Cardiovasc Surg 1994;108(4): [7] Reul Jr GJ, Cooley DA, Duncan JM, Frazier OH, Hallman GL, Livesay JJ, Ott DA, Walker WE. Valve failure with the Ionescu- Shiley bovine pericardial bioprosthesis: analysis of 2680 patients. J Vasc Surg 1985;2(1): [8] Czer LS, Matloff JM, Chaux A, DeRobertis MA, Gray RJ. Comparative clinical experience with porcine bioprosthetic and St Jude valve replacement. Chest 1987;91(4): [9] Edmunds Jr LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. The American Association for Thoracic Surgery, Ad Hoc Liason Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Ann Thorac Surg 1996;62(3): [10] Khan S, Trento A, Kass R, DeRobertis M, Sandhu M, Nessim S. Actual failure rates: a method of assessing tissue valve reoperation rates. Am Heart J 1999;138(1 Pt 1): [11] Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29(3): [12] Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994;15(7): [13] Borkon AM, Soule LM, Baughman KL, Baumgartner WA, Gardner TJ, Watkins L, Gott VL, Hall KA, Reitz BA. Aortic valve selection in the elderly patient. Ann Thorac Surg 1988;46(3): [14] Cohn LH, Couper GS, Aranki SF, Kinchla NM, Collins Jr JJ. The long-term follow-up of the Hancock Modified Orifice porcine bioprosthetic valve. J Cardiac Surg 1991;6(Suppl 4): [15] Akins CW, Carroll DL, Buckley MJ, Daggett WM, Hilgenberg AD, Austen WG. Late results with Carpentier-Edwards porcine bioprosthesis. Circulation 1990;82(Suppl 5):IV65 IV74. [16] Tyers GF, Jamieson WR, Munro AI, Germann E, Burr LH, Miyagishima RT, Ling H. Reoperation in biological and mechanical valve populations: fate of the reoperative patient. Ann Thorac Surg 1995;60(Suppl 2):S discussion S [17] Jamieson WR, Burr LH, Miyagishima RT, Fradet GJ, Janusz MT, Tyers FO, MacNab J, Chan F. Structural deterioration in Carpentier- Edwards standard and supraannular porcine bioprostheses. Ann Thorac Surg 1995;60(Suppl 2):S [18] Cohn LH, DiSesa VJ, Collins Jr JJ. The Hancock modified-orifice porcine bioprosthetic valve: Ann Thorac Surg 1989; 48(Suppl 3):S81 2. [19] Burdon TA, Miller DC, Oyer PE, Mitchell RS, Stinson EB, Starnes VA, Shumway NE. Durability of porcine valves at fifteen years in a representative North American patient population. J Thorac Cardiovasc Surg 1992;103(2): discussion [20] Burr LH, Jamieson WR, Munro AI, Miyagishima RT, Germann E. Porcine bioprostheses in the elderly: clinical performance by age groups and valve positions. Ann Thorac Surg 1995;60(Suppl 2): S [21] Fann JI, Miller DC, Moore KA, Mitchell RS, Oyer PE, Stinson EB, Robbins RC, Reitz BA, Shumway NE. Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg 1996; 62(5): discussion [22] Corbineau H, Du Haut Cilly FB, Langanay T, Verhoye JP, Leguerrier A. Structural durability in Carpentier Edwards Standard bioprosthesis
7 370 M. Ruel et al. / European Journal of Cardio-thoracic Surgery 25 (2004) in the mitral position: a 20-year experience. J Heart Valve Dis 2001; 10(4): [23] Helft G, Tabone X, Georges JL, Lomama E, Nematalla H, Metzger JP, Heulin A, Vacheron A. Bioprosthetic valve replacement in the elderly. Eur Heart J 1995;16(4): [24] Glower DD, White WD, Hatton AC, Smith LR, Young WG, Wolfe WG, Lowe JE. Determinants of reoperation after 960 valve replacements with Carpentier-Edwards prostheses. J Thorac Cardiovasc Surg 1994;107(2): discussion [25] Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997;78(5): Appendix A. Conference discussion Dr P. Skarsgard (Vancouver, Canada): Did you find any increased rate of structural valve deterioration according to size in the mitral position? Dr Ruel: No, we did not. The relationship we observed with aortic bioprostheses was not present with mitral bioprostheses; there was not even a trend. Dr S. Bolling (Ann Arbor, Michigan): Were you able to analyze how many of these patients were on statins? There is sort of a trend in some of the literature now to analyze reoperative rates, valve degeneration rates on the basis of statins, and even statin dose in some of these patients. If this is a modern series we should be able to analyze which patients were on statins and does that have an influence on valve degeneration. Dr Ruel: You are absolutely right that both native and prosthetic valve literatures now suggest that hypercholesterolemia may have a detrimental effect on valve deterioration. Unfortunately we do not have this data available. Dr K. Wrobel (Krakow, Poland): Did you analyze the rate of urgency reoperation compared between the groups and did you try to identify any risk factors for urgent reoperation in both groups? Dr Ruel: No, we did not look at that. As one would expect, the vast majority of those reoperations were electively performed for progressive structural valve deterioration. There were a few urgent reoperations, especially with discontinued models like the Ionescu-Shiley whose failure could happen very suddenly, but in the recent part of the series there were quite few reoperations which were performed urgently. Dr E. Al-Mashat (Baghdad, Iraq): Have you tried to correlate the degeneration with the possibility of the etiologic cause for the pathology? It has been our observation in Iraq that no matter how good the bioprosthesis is, it gets degenerated quicker, perhaps our main pathology being rheumatic heart disease and age of our patients is much younger than yours. What is your comment on this? Dr Ruel: It is an interesting hypothesis that perhaps some preformed antibodies as the result of rheumatic fever may play a role in bioprosthetic valve degeneration, but we have not been in a position to look at this in our series.
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationDurability of Pericardial Versus Porcine Aortic Valves
Journal of the American College of Cardiology Vol. 44, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.053
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationLate incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves
Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves Marc Ruel, MD, MPH a,b Fraser D. Rubens, MD a Roy G. Masters, MD a Andrew L. Pipe, MD a
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationSurgery for Valvular Heart Disease. Reoperation of Left Heart Valve Bioprostheses According to Age at Implantation
Surgery for Valvular Heart Disease Reoperation of Left Heart Valve Bioprostheses According to Age at Implantation Vincent Chan, MD, MPH; Tarek Malas, MD; Harry Lapierre, MD; Munir Boodhwani, MMSc, MD;
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationThe advantages and disadvantages of mechanical valve prostheses and
Surgery for Acquired Cardiovascular Disease Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients Ye-Ying Cen, MA Donald D. Glower, MD Kevin Landolfo,
More informationLONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS
LONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS David S. Peterseim, MD Ye-Ying Cen, MA Srinivas Cheruvu, MHS Kevin Landolfo, MD Thomas M. Bashore, MD James E.
More informationRead at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.
STRUCTURAL VALVE DETERIORATION IN MITRAL REPLACEMENT SURGERY: COMPARISON OF CARPENTIER-EDWARDS SUPRA-ANNULAR PORCINE AND PERIMOUNT PERICARDIAL BIOPROSTHESES W. R. Eric Jamieson, MD a Michel A. Marchand,
More informationby Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D., L. H. Burr, M.D., R. T. Miyagishima, M.D.
Carpentier-Edwards Standard Porcine Bioprosthesis: Primary Tissue Failure (Structural Valve Deterioration) by Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D.,
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationSurgery for Acquired Cardiovascular Disease
Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement W. R. E. Jamieson, MD, O. von Lipinski, MD, R. T.
More informationP have been used for mitral and aortic valve replacement
A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani,
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationNearly 40 years after the pioneering efforts of Starr and
Prognosis After Aortic Valve Replacement With a Bioprosthesis Predictions Based on Meta-Analysis and Microsimulation J.P.A. Puvimanasinghe, MBBS, MSc, MD; E.W. Steyerberg, PhD; J.J.M. Takkenberg, MD; M.J.C.
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationControversy exists regarding which valve type is best
Treatment of Endocarditis With Valve Replacement: The Question of Tissue Versus Mechanical Prosthesis Marc R. Moon, MD, D. Craig Miller, MD, Kathleen A. Moore, BS, Phillip E. Oyer, MD, PhD, R. Scott Mitchell,
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationThe clinical experience reported in recent Western series has provided
Surgery for Acquired Cardiovascular Disease Yu et al Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease Hsi-Yu Yu, MD a Yi-Lwun Ho, MD b Shu-Hsun Chu, MD c Yih-Sharng
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More informationThe use of mitral valve (MV) repair to correct mitral
Outcomes and Long-Term Survival for Patients Undergoing Repair Versus Effect of Age and Concomitant Coronary Artery Bypass Grafting Vinod H. Thourani, MD; William S. Weintraub, MD; Robert A. Guyton, MD;
More informationI will not discuss off label use or investigational use in my presentation.
I will not discuss off label use or investigational use in my presentation. Surgical valves Design and Durability Testing Potential Concerns Real Practice 1952-1962 1963-1966 1967-1969 1969-1977 1977-1984
More informationAccepted Manuscript. Does valve choice matter in hemodialysis patients? Weiang Yan, MD, Rakesh C. Arora, MD, PhD, Michael H. Yamashita, MDCM, MPH
Accepted Manuscript Does valve choice matter in hemodialysis patients? Weiang Yan, MD, Rakesh C. Arora, MD, PhD, Michael H. Yamashita, MDCM, MPH PII: S0022-5223(18)32559-5 DOI: 10.1016/j.jtcvs.2018.09.055
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationThe operative mortality associated with repeat heart valve surgery is. Repeat heart valve surgery: Risk factors for operative mortality
Surgery for Acquired Cardiovascular Disease Repeat heart valve surgery: Risk factors for operative mortality J. Mark Jones, MA, AFRCS a Hugh O Kane, MCh, FRCS a Dennis J. Gladstone, FRCS a Mazin A. I.
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationSotirios N. Prapas, M.D., Ph.D, F.E.C.T.S.
CORONARY ARTERY REVASCULARIZATION WITH MILD AORTIC STENOSIS: STRATEGIES OF TREATMENT 9 th ANNUAL MEETING OF THE EAB SOCIETY, Pravets, Bulgaria, 2012 Sotirios N. Prapas, M.D., Ph.D, F.E.C.T.S. Director
More informationThe impact of prosthesis patient mismatch after aortic valve replacement varies according to age at operation
Editor s choice Scan to access more free content 1 Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, Maryland, USA 2 Division of Cardiac Surgery, University of Ottawa Heart Institute,
More informationPrimary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: Hancock I Vekus Carpentier-Edwards at 4- to 7-Years Follow-up
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: A Hancock I Vekus Edwards at 4- to 7-Years Follow-up Francisco Nistal, M.D., Edurne Artifiano, M.D., and Ignacio Gallo,
More informationValve prosthesis-patient mismatch (PPM) was first defined
Impact of Valve Prosthesis-Patient Mismatch on Short-Term Mortality After Aortic Valve Replacement Claudia Blais, BSc; Jean G. Dumesnil, MD; Richard Baillot, MD; Serge Simard, MS; Daniel Doyle, MD; Philippe
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationMitral valve replacement in patients under 65 years of age: mechanical or biological valves?
REVIEW C URRENT OPINION Mitral valve replacement in patients under 65 years of age: mechanical or biological valves? David C. Reineke, Paul Philipp Heinisch, Bernhard Winkler, Lars Englberger, and Thierry
More informationCONTRIBUTION. Aortic valve replacement in young patients: long-term follow-up
CONTRIBUTION Aortic valve replacement in young patients: long-term follow-up DOUGLAS S. MOODIE, MD; USAMA HANHAN, MD; RICHARD STERBA, MD; DANIEL J. MURPHY, Jr, MD; ELIOT R. ROSENKRANZ, MD; ANDREA M. KOVACS,
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationDeterminants of reoperation after 960 valve replacements with Carpentier-Edwards prostheses
Surgery for Acquired Heart Disease Determinants of reoperation after 96 valve replacements with Carpentier-dwards prostheses During the period of 1977 to 199, 96 Carpentier-dwards standard prostheses (Baxter
More informationNatural History and Predictors of Outcome in Patients With Concomitant Functional Mitral Regurgitation at the Time of Aortic Valve Replacement
Natural History and Predictors of Outcome in Patients With Concomitant Functional Mitral Regurgitation at the Time of Aortic Valve Replacement Marc Ruel, MD, MPH; Varun Kapila, MD; Joel Price, MD; Alexander
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28521 holds various files of this Leiden University dissertation Author: Katsanos, Spyridon Title: Outcomes of transcatheter aortic valve implantation Issue
More informationAortic valve replacement: is porcine or bovine valve better?
Interactive CardioVascular and Thoracic Surgery Advance Access published December 4, 2012 Interactive CardioVascular and Thoracic Surgery (2012) 1 13 doi:10.1093/icvts/ivs447 BEST EVIDENCE TOPIC Aortic
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationReoperations after primary aortic valve replacement
Third-Time Aortic Valve Replacement: Patient s and Operative Outcome Kasra Shaikhrezai, MD, MRCS, Giordano Tasca, MD, FETCS, Mohamed Amrani, PhD, FETCS, Gilles Dreyfus, MD, FETCS, and George Asimakopoulos,
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationStandarized definition of bioprosthetic valve deterioration and failure
Translational aortic valve research. From biology to treatment Standarized definition of bioprosthetic valve deterioration and failure Anna Sonia Petronio, MD, FESC Head of Cardiac Catheterization Lab
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationAcquired Cardiovascular Disease
Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database James M. Brown,
More informationThe increase in the lifespan of the western population
Outcome After Aortic Valve Replacement in Octogenarians Bruno Chiappini, MD, Nicola Camurri, MD, Antonio Loforte, MD, Luca Di Marco, MD, Roberto Di Bartolomeo, MD, and Giuseppe Marinelli, MD Department
More informationMitral Valve Surgery: Lessons from New York State
Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman & Program Director Department of Cardiovascular
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationLong-term relative survival after primary heart valve replacement 1
European Journal of Cardio-thoracic Surgery 11 (1997) 81 91 Long-term relative survival after primary heart valve replacement 1 Abstract E. Ståhle a, *, P. Kvidal b, S.O. Nyström a, R. Bergström c a Department
More informationValvular Disease in the Elderly: Influence on Surgical Results
ORIGINAL ARTICLES Valvular Disease in the Elderly: Influence on Surgical Results Elizabeth A. Davis, MD, Timothy J. Gardner, MD, A. Marc Gillinov, MD, William A. Baumgartner, MD, Duke E. Cameron, MD, Vincent
More informationHemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years
Hemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years Friedrich-Christian Riess, MD, Ralf Bader, MD, Eva Cramer, MD, Lorenz Hansen, MD, Bèr Kleijnen, MS, Gunther Wahl, MD,
More informationAortic stenosis (AS) is common with the aging population.
New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting
More informationBioprostheses are prone to continuous degeneration
Twenty-Year Experience With the St. Jude Medical Biocor Bioprosthesis in the Aortic Position Walter B. Eichinger, MD, Ina M. Hettich, MD, Daniel J. Ruzicka, MD, Klaus Holper, MD, Carolin Schricker, Sabine
More informationPatient prosthesis mismatch after mitral valve replacement: Myth or reality?
Patient prosthesis mismatch after mitral valve replacement: Myth or reality? Pasquale Totaro, MD, a and Vincenzo Argano, MD b Objective: Determining the risk of patient prosthesis mismatch after mitral
More informationHypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation
Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation Robert Saeid Farivar, MD, PhD Lawrence H. Cohn, MD Objective: There are pathophysiologic similarities between
More informationRegression of Hypertrophy After Carpentier-Edwards Pericardial Aortic Valve Replacement
Regression of Hypertrophy After Carpentier-Edwards Pericardial Aortic Valve Replacement Steven S. Khan, MD, Robert J. Siegel, MD, Michele A. DeRobertis, RN, Carlos E. Blanche, MD, Robert M. Kass, MD, Wen
More informationP substitutes since the introduction of the Ionescu-
Mitroflow Pericardial Valve: Long-Term Durability Daniel Y. Loisance, MD, Jean-Philippe Mazzucotelli, MD, Patrick C. Bertrand, MD, Philippe H. Deleuze, MD, and Jean-Paul Cachera, MD Department of Surgical
More informationA prospective evaluation of the Bjbrk-Shiley, Hancock, and Carpentier-Edwards heart valve prostheses
THERAPY AND PREVENTION VALVE REPLACEMENT A prospective evaluation of the Bjbrk-Shiley, Hancock, and Carpentier-Edwards heart valve prostheses PETER BLOOMFIELD, M.R.C.P., ARTHUR H. KITCHIN, F.R.C.P.. DAVID
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationMitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease
Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease Kenji Kuwaki, MD, PhD, Nobuyoshi Kawaharada, MD, PhD, Kiyofumi Morishita, MD, PhD, Tetsuya Koyanagi,
More informationAspirin or Coumadin as the Drug of Choice
Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis L. Nufiez, M.D., M. Gil Aguado, M.D., D. Celemin, M.D., A. Iglesias, M.D., and J. L. Larrea, M.D. ABSTRACT Eight
More informationEcho Evaluation of a Mitral Valve Prostheses Sunday, February 14, :50 2:10 PM 20 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ Echo Evaluation of a Mitral Valve Prostheses Sunday, February 14, 2016 1:50 2:10 PM 20 min 1 M U H A M E D S A R I Ć, M D, P H D D i r e c t
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationCARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP
CARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP M. R. Aupart, MD P. H. Neville, MD S. Hammami, MD A. L. Sirineili, MD Y. A. Meurisse, MD M. A. Marchand, MD Objective: The
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationBiological or mechanical valve prosthesis?
XXIX Giornate Cardiologiche Torinesi ADVANCES IN CARDIAC ARRHYTHMIAS AND GREAT INNOVATIONS IN CARDIOLOGY Turin, October 27-28, 2017 Centro Congressi Unione Industriale WHAT HAS CHANGED IN CARDIAC SURGERY?
More informationPorcine bioprosthesis use for surgical treatment of
Fifteen-Year Clinical Experience With the Biocor Porcine Bioprostheses in the Mitral Position Kaan Kırali, MD, Mustafa Güler, MD, Altuğ Tuncer, MD, Bahadır Dağlar, MD, Gökhan İpek, MD, Ömer Işık, MD, and
More informationTwenty-year experience with the St Jude Medical mechanical valve prosthesis
Surgery for Acquired Cardiovascular Disease Ikonomidis et al Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S. Ikonomidis, MD, PhD John M. Kratz, MD Arthur J. Crumbley
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More informationIn , three studies described patients
Heart 2001;85:337 341 VALVE DISEASE Should patients with asymptomatic mild or moderate aortic stenosis undergoing coronary artery bypass surgery also have valve replacement for their aortic stenosis? Shahbudin
More informationPrognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards
European Heart Journal Supplements (1) 3 (Supplement Q), Q27 Q32 Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding
More informationExtension to medium and low risk patients? Friedrich Eckstein University Hospital Basel
TAVI CON Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel Extension to medium and low risk patients? In octogenerians already reality in most of the swiss clinics!?
More informationD derly population has consisted chiefly of evaluation
Cardiac Valve Replacement in the Elderly: Clinical Perf ormance of Biological Prostheses W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, A. Ian Munro, MD, Robert T. Miyagishima, MD, and Alfred N. Gerein,
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationMechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation
Mechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation Ho Young Hwang, MD, PhD, Kyung-Hwan Kim, MD, PhD, Ki-Bong Kim, MD, PhD, and Hyuk
More informationS ince the two large randomised trials of the 1970s
23 CARDIOVASCULAR MEDICINE Mid term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves I Florath, A Albert, U Rosendahl, T Alexander,
More information